Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation

Xin Sun; Wenjuan Chen; Xiujuan Qu; Xiujuan Qu; Xiujuan Qu; Xiujuan Qu; Ying Chen; Ying Chen; Ying Chen; Ying Chen

doi:10.3389/fphar.2022.968060

Frontiers in Pharmacology (Aug 2022)

Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation

Xin Sun,
Wenjuan Chen,
Xiujuan Qu,
Xiujuan Qu,
Xiujuan Qu,
Xiujuan Qu,
Ying Chen,
Ying Chen,
Ying Chen,
Ying Chen

Affiliations

Xin Sun: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
Wenjuan Chen: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
Xiujuan Qu: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
Xiujuan Qu: Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
Xiujuan Qu: Liaoning Province Clinical Research Center for Cancer, Shenyang, China
Xiujuan Qu: Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, China
Ying Chen: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
Ying Chen: Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
Ying Chen: Liaoning Province Clinical Research Center for Cancer, Shenyang, China
Ying Chen: Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, China

DOI: https://doi.org/10.3389/fphar.2022.968060
Journal volume & issue: Vol. 13

Abstract

Read online

Background: Poly ADP-ribose polymerase inhibitors (PARPis) are widely used for patients with BRCA1/2 mutations. However, until now, there is no available evidence reported for the efficiency of PARPis in cutaneous squamous cell carcinoma (cSCC).Case presentation: We presented a case of a 40-year-old man diagnosed with metastatic cSCC, relapsing after multiple lines of chemotherapy. Liquid biopsy detected a BRCA2 pathogenic germline mutation (c.3109C > T), indicating PARPis might be effective for this patient. The patient achieved tumor stability, and progression-free survival was five months without severe adverse effects after taking fluzoparib.Conclusion: This result confirmed that PARPis were effective for metastatic cSCC patients with germline BRCA2 pathogenic mutations and provided a new treatment option for this group of patients.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords